Vistagen Therapeutics (VTGN) earnings call transcripts

Management framed the failed overall Phase III readout as a reason to reassess the endpoint and pursue a different regulatory path, while stressing post-hoc subgroup findings.

Management framed the quarter around learning from Palisade III, tightening Palisade IV execution, and building analyses that could inform regulatory strategy.

Management framed the call around an imminent Palisade 3 readout and a potentially pivotal transition toward an NDA and commercialization planning.